[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"reproductive-age\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:reproductive-age":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,48,67,85],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100577038","functional-proteins-in-polycystic-ovary-syndrome-100577038",false,"NCT06793098","Functional Proteins in Polycystic Ovary Syndrome","Assessment of the Concentrations of Functional Proteins as Potential Early Markers of Insulin Resistance in Women With Polycystic Ovary Syndrome","Inclusion Criteria:\n\n* women aged 18-45 years\n\nExclusion Criteria:\n\n* removal of at least one ovary\n* treated diabetes of any type\n* diagnosed and treated metabolic diseases\n* diagnosed and treated autoimmune diseases\n* diagnosed and treated autoinflammatory diseases",true,"FEMALE","18 Years","45 Years",{"count":21,"type":22},100,"ESTIMATED","OBSERVATIONAL","The concentration of functional proteins: kisspeptin, ghrelin, zonulin will be measured and compared in women with polycystic ovary syndrome (PCOS) and insulin resistance (IR), in women with PCOS without IR, and in women without PCOS.",[26,27],"Reproductive Age","PCOS (Polycystic Ovary Syndrome)",[29,30,31,32,33,34],"insulin resistance","kisspeptin","ghrelin","zonulin","metabolic syndrome","Polycystic Ovary Syndrome","RECRUITING","2026-03-17",{"date":38,"type":39},"2026-03-18","ACTUAL",{"date":41,"type":39},"2025-01-20",{"date":43,"type":22},"2027-12-31",{"name":45,"class":46},"Jagiellonian University","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":63,"startDateStruct":64,"completionDateStruct":65,"leadSponsor":66,"locationsCount":47},"100577036","adipokines-in-polycystic-ovary-syndrome-100577036","NCT06793072","Adipokines in Polycystic Ovary Syndrome","Assessment of Adipokine Concentrations and Their Association With the Metabolic Profile of Women With PCOS","Inclusion Criteria:\n\n* Age 18-45\n\nExclusion Criteria:\n\n* previous removal of at least one ovary\n* treated diabetes of any type\n* diagnosed and treated metabolic diseases\n* diagnosed and treated autoimmune diseases\n* diagnosed and treated autoinflammatory diseases(Edited)Restore original",{"count":56,"type":22},300,"The aim of the study is to compare the concentrations of leptin, resistin, and omentin-1 in women across three research groups: those with polycystic ovary syndrome without insulin resistance, those with polycystic ovary syndrome with insulin resistance, and women without polycystic ovary syndrome.",[59,26],"PCOS",[29,61,33,62],"polycystic ovary syndrome","adipokines",{"date":38,"type":39},{"date":41,"type":39},{"date":43,"type":22},{"name":45,"class":46},{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":74,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":75,"conditions":76,"keywords":77,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":80,"startDateStruct":81,"completionDateStruct":82,"leadSponsor":84,"locationsCount":47},"100577037","pro--and-anti-inflammatory-cytokines-in-pcos-100577037","NCT06793085","Pro- and Anti-inflammatory Cytokines in PCOS","Assessment of the Concentrations of Pro- and Anti-inflammatory Cytokines and Their Association With the Metabolic Profile of Women With PCOS","Inclusion Criteria:\n\n* women aged 18-45 years\n\nExclusion Criteria:\n\n* previous removal of at least one ovary\n* treated diabetes of any type\n* diagnosed and treated metabolic diseases\n* diagnosed and treated autoimmune diseases\n* diagnosed and treated autoinflammatory diseases",{"count":21,"type":22},"The study will involve measurements and comparisons of the concentrations of pro-inflammatory cytokines: IL-6, TNF-α, IL-18, as well as anti-inflammatory cytokine IL-4 in women with polycystic ovary syndrome (PCOS) and insulin resistance, women with polycystic ovary syndrome without carbohydrate metabolism disorders, and women without PCOS (control group).",[26,27],[78,79,29,33,34],"menstrual disorders","chronic inflammation",{"date":38,"type":39},{"date":41,"type":39},{"date":83,"type":22},"2026-12-31",{"name":45,"class":46},{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":93,"enrollmentInfo":94,"targetDuration":96,"studyType":23,"phases":4,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":47},"100570651","study-on-fertility-parameters-in-women-with-germline-variants-in-brca1-and-brca2-100570651","NCT06710015","Study on Fertility Parameters in Women With Germline Variants in BRCA1 and BRCA2","B.Fert: Retrospective and Prospective Observational Study on Fertility Parameters in Women With Germline Variants in BRCA1 and BRCA2","BFert","BRCA1 and BRCA2 carriers\n\nInclusion Criteria:\n\n* age \\> 18 years\n* presence of a pathogenic variant in the BRCA genes\n* signed informed consent Exclusion Criteria\n* presence of a pathogenic variant in another gene (not BRCA)\n* significant psychiatric or clinical impairment affecting the ability to consent to the study\n\nControl cohort\n\nInclusion Criteria:\n\n\\- Relatives up to the third degree of the first cohort who tested negative on predictive testing for the familial pathogenic variant in the BRCA genes, matched for age where possible.\n\nExclusion Criteria:\n\n* absence of a pathogenic variant in another gene (non-BRCA) found in a family member\n* significant psychiatric or clinical impairment affecting the ability to consent to the study","100 Years",{"count":95,"type":22},128,"1 Day","Pathogenic variants (PVs) in the BRCA1 and BRCA2 genes are associated with an increased risk of developing breast and ovarian cancers. According to current guidelines from the National Comprehensive Cancer Network, the risk of developing breast cancer exceeds 60% for both genes, while the risk for ovarian cancer ranges from 39% to 58% for the BRCA1 and from 13% to 29% for the BRCA2. The detection of a pathogenic variant in the BRCA1 or BRCA2 genes necessitates both the establishment of appropriate primary and secondary surveillance measures for carriers and the discussion of the familial implications of such findings.\n\nThe molecular basis initially suggesting a possible association between germline variants in BRCA1 and BRCA2 genes and diminished ovarian reserve lies in the cellular impact of impaired or defective repair of DNA double-strand breaks (DSBs) on oocytes. Notably, BRCA1 and BRCA2 genes play a key role in the ATM-related mechanism for DSB repair through the homologous recombination (HR) pathway.\n\nAlthough preclinical evidence supports a potential correlation between defective DSB repair and normal follicle maturation processes, clinical studies on large cohorts of patients with pathogenic BRCA1 and BRCA2 variants yield inconsistent results. This discrepancy is likely attributable to the inherent challenges in recruiting a sufficiently homogeneous and statistically significant sample size.\n\nThe aim of the study is to evaluate reproductive capacity in women carrying pathogenic variants in the BRCA1\u002F2 genes by assessing the number of pregnancies during the period from January 1, 2018, to December 31, 2023. Secondary objectives include evaluating menopausal characteristics and pregnancy outcomes.",[99,100,26,101,102],"BRCA1 and\u002For BRCA2 Variant Carriers","Fertility","Menopause","Pregnancy Outcomes","NOT_YET_RECRUITING","2024-11-26",{"date":106,"type":39},"2024-11-29",{"date":108,"type":22},"2024-12-01",{"date":110,"type":22},"2026-06-01",{"name":112,"class":46},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS"]